Lijing Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lijing Fang has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Chunlei Wu
Guangdong Key Laboratory of Nanomedicine, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China
10 shared publicationsHongchang Li
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials
9 shared publicationsKe Liu
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials
9 shared publications- Wu Su
Center for Innovative Drug Discovery Greater Bay Area Institute of Precision Medicine (Guangzhou) Guangzhou 528441 P. R. China
9 shared publications Meiqing Li
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, China
8 shared publicationsYanyan Li
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
7 shared publications
Latest Publications
- 13 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41) , e71836
Coordination Reprogramming of Fe‐Antibiotic Assemblies Enables Valence‐Gated β‐Lactam Reactivation
Reactivating legacy antibiotics offers a practical route to combat drug‐resistant infections, but requires delivery systems that coordinate bacterial engagement with pathogen‐triggered drug release. Here, we report DFC, a deferoxamine (DFO)‐reprogrammed Fe‐carbenicillin (Car) coordination nanoassembly that restores the activity of the legacy β‐lactam antibiotic Car against MRSA. DFC was fabricated via DFO‐mediated competitive coordination, transforming homogeneous Fe‐Car networks into heterogeneous Car‐Fe‐DFO structures. Computational modeling and spectroscopic analyses showed stronger Fe 3+ ‐DFO affinity than Fe 3+ ‐Car binding, DFO‐induced redistribution of the Fe‐centered ligand environment, and sharply weakened Fe‐ligand stability after Fe 3+ ‐to‐Fe 2+ conversion. This coordination reprogramming allowed DFC to remain assembled under nonreducing conditions but rapidly disassemble and release Car under reducing conditions or upon exposure to MRSA. DFC enhanced MRSA targeting, biofilm penetration, and intracellular Fe/Car‐associated accumulation, while Fe‐valence‐triggered destabilization promoted Car release, disrupted iron homeostasis, amplified oxidative stress and lipid peroxidation, and damaged the bacterial envelope. Collectively, these synergistic effects re‑established β‐lactam susceptibility, conferred robust antibacterial and anti‑biofilm efficacy, and markedly promoted pathogen clearance as well as tissue repair, as evidenced in both infected wound and osteomyelitis models. This study establishes competitive coordination reprogramming as a chemical strategy for coupling bacterial iron metabolism with antibiotic liberation and resistance reversal.
- 13 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (41) , e71836
Coordination Reprogramming of Fe‐Antibiotic Assemblies Enables Valence‐Gated β‐Lactam Reactivation
Reactivating legacy antibiotics offers a practical route to combat drug‐resistant infections, but requires delivery systems that coordinate bacterial engagement with pathogen‐triggered drug release. Here, we report DFC, a deferoxamine (DFO)‐reprogrammed Fe‐carbenicillin (Car) coordination nanoassembly that restores the activity of the legacy β‐lactam antibiotic Car against MRSA. DFC was fabricated via DFO‐mediated competitive coordination, transforming homogeneous Fe‐Car networks into heterogeneous Car‐Fe‐DFO structures. Computational modeling and spectroscopic analyses showed stronger Fe 3+ ‐DFO affinity than Fe 3+ ‐Car binding, DFO‐induced redistribution of the Fe‐centered ligand environment, and sharply weakened Fe‐ligand stability after Fe 3+ ‐to‐Fe 2+ conversion. This coordination reprogramming allowed DFC to remain assembled under nonreducing conditions but rapidly disassemble and release Car under reducing conditions or upon exposure to MRSA. DFC enhanced MRSA targeting, biofilm penetration, and intracellular Fe/Car‐associated accumulation, while Fe‐valence‐triggered destabilization promoted Car release, disrupted iron homeostasis, amplified oxidative stress and lipid peroxidation, and damaged the bacterial envelope. Collectively, these synergistic effects re‑established β‐lactam susceptibility, conferred robust antibacterial and anti‑biofilm efficacy, and markedly promoted pathogen clearance as well as tissue repair, as evidenced in both infected wound and osteomyelitis models. This study establishes competitive coordination reprogramming as a chemical strategy for coupling bacterial iron metabolism with antibiotic liberation and resistance reversal.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Hollow MnO2 Nanozyme with NO Prodrug to Boost Synergistic CDT/PDT/Gas Therapy via Oxidative Stress Cascade
Purpose: Photodynamic therapy (PDT) utilizes photosensitizers to generate reactive oxygen species (ROS) to kill tumors. However, the tumor’s hypoxia and the limitations of a single ROS mechanism severely restrict its efficacy. This study aims to develop a synergistic nano-catalytic system (HMO) based on hollow manganese dioxide (HMnO2) loaded with a novel nitric oxide (NO) donor (Methylene Blue - NO, MB-NO), which overcomes these obstacles through multiple synergistic effects. Methods: Preliminary experiments confirmed the synthesis of HMO. Systematic studies were conducted on the chemodynamic therapy (CDT)/PDT/NO properties of HMO as well as its anti-tumor activity in vivo and in vitro. Finally, the in vivo safety of HMO was evaluated. Results: Preparation by the HMO is 189 nm nano particle size, Zeta potential for −37 ± 1.4 mV, exhibit excellent stability. In vitro experiments showed that the cellular uptake of HMO was time-dependent. In terms of cytotoxicity, the cell survival rate of the HMO group was 65.9%, significantly lower than that of the free HMnO2 (89.1%) and MB-NO (85.1%); after 5 min of 660 nm laser irradiation, the cell survival rate of the HMO group further dropped to 48.5%. In the animal experiments of tumor xenograft models, the tumor inhibition rate of the HMO combined with 660 nm laser irradiation for 5 min group was as high as 81.3%, and it did not cause acute inflammation in the main organs, demonstrating good biological safety. In summary, the HMO nanoparticles exhibit excellent anti-tumor effects. Conclusion: This strategy combines CDT/PDT/gas therapy, enabling the synergistic cascade of NO/ROS/reactive nitrogen oxide species (RNOS) to promote tumor cell apoptosis and inhibit tumor growth, thereby achieving a cascading amplification of therapeutic effects and providing a treatment solution to overcome the inherent limitations of traditional photodynamic therapy.
- 1 July 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Open AccessHollow MnO2 Nanozyme with NO Prodrug to Boost Synergistic CDT/PDT/Gas Therapy via Oxidative Stress Cascade
Purpose: Photodynamic therapy (PDT) utilizes photosensitizers to generate reactive oxygen species (ROS) to kill tumors. However, the tumor’s hypoxia and the limitations of a single ROS mechanism severely restrict its efficacy. This study aims to develop a synergistic nano-catalytic system (HMO) based on hollow manganese dioxide (HMnO2) loaded with a novel nitric oxide (NO) donor (Methylene Blue - NO, MB-NO), which overcomes these obstacles through multiple synergistic effects. Methods: Preliminary experiments confirmed the synthesis of HMO. Systematic studies were conducted on the chemodynamic therapy (CDT)/PDT/NO properties of HMO as well as its anti-tumor activity in vivo and in vitro. Finally, the in vivo safety of HMO was evaluated. Results: Preparation by the HMO is 189 nm nano particle size, Zeta potential for −37 ± 1.4 mV, exhibit excellent stability. In vitro experiments showed that the cellular uptake of HMO was time-dependent. In terms of cytotoxicity, the cell survival rate of the HMO group was 65.9%, significantly lower than that of the free HMnO2 (89.1%) and MB-NO (85.1%); after 5 min of 660 nm laser irradiation, the cell survival rate of the HMO group further dropped to 48.5%. In the animal experiments of tumor xenograft models, the tumor inhibition rate of the HMO combined with 660 nm laser irradiation for 5 min group was as high as 81.3%, and it did not cause acute inflammation in the main organs, demonstrating good biological safety. In summary, the HMO nanoparticles exhibit excellent anti-tumor effects. Conclusion: This strategy combines CDT/PDT/gas therapy, enabling the synergistic cascade of NO/ROS/reactive nitrogen oxide species (RNOS) to promote tumor cell apoptosis and inhibit tumor growth, thereby achieving a cascading amplification of therapeutic effects and providing a treatment solution to overcome the inherent limitations of traditional photodynamic therapy.
- 9 June 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (6) , 823-836.e21
Structure-based design of Sec61 translocon targeting prodrugs minimize off-target toxicity
- 9 June 2026
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (6) , 823-836.e21
Structure-based design of Sec61 translocon targeting prodrugs minimize off-target toxicity
- 20 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5691-5702
Coibamide Analogue as a Novel-Class Payload for Antibody-Drug Conjugate
Although antibody-drug conjugates (ADCs) have made substantial progress as targeted therapies, the range of suitable ADC payloads remains limited. In this study, the highly N-methylated cyclodepsipeptide [MeAla3-MeAla6]-coibamide (CA) was selected as a novel toxin for ADC construction due to its potent toxicity and unique mechanism of action. Using a quaternary ammonium salt approach, two linker-payload variants, MC-VA-PAB-CA and MC-GGFG-PAB-CA, with distinct cathepsin B (CTB)-cleavable linkers, were synthesized and assessed. Among them, MC-GGFG-PAB-CA demonstrated higher enzyme-responsive cleavage efficiency and superior plasma stability and was selected for conjugation with the epidermal growth factor receptor (EGFR) antibody cetuximab (Ctx), resulting in the formation of Ctx-CA. This conjugate exhibited EGFR-dependent antitumor activity, a pronounced "bystander killing effect", and a significant tumor suppression effect in mouse models. Furthermore, the applicability of this conjugation strategy was confirmed through validation with the HER2 antibody. These findings suggest that CA is a promising weapon for next-generation ADCs.
- 20 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5691-5702
Coibamide Analogue as a Novel-Class Payload for Antibody-Drug Conjugate
Although antibody-drug conjugates (ADCs) have made substantial progress as targeted therapies, the range of suitable ADC payloads remains limited. In this study, the highly N-methylated cyclodepsipeptide [MeAla3-MeAla6]-coibamide (CA) was selected as a novel toxin for ADC construction due to its potent toxicity and unique mechanism of action. Using a quaternary ammonium salt approach, two linker-payload variants, MC-VA-PAB-CA and MC-GGFG-PAB-CA, with distinct cathepsin B (CTB)-cleavable linkers, were synthesized and assessed. Among them, MC-GGFG-PAB-CA demonstrated higher enzyme-responsive cleavage efficiency and superior plasma stability and was selected for conjugation with the epidermal growth factor receptor (EGFR) antibody cetuximab (Ctx), resulting in the formation of Ctx-CA. This conjugate exhibited EGFR-dependent antitumor activity, a pronounced "bystander killing effect", and a significant tumor suppression effect in mouse models. Furthermore, the applicability of this conjugation strategy was confirmed through validation with the HER2 antibody. These findings suggest that CA is a promising weapon for next-generation ADCs.
- 8 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130496
Bicyclic peptide-based CPPTACs for extracellular and cell membrane protein degradation
- 8 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130496
Bicyclic peptide-based CPPTACs for extracellular and cell membrane protein degradation
- 8 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130504
A self-assembling peptide platform enables plasma membrane protein degradation
- 8 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130504
A self-assembling peptide platform enables plasma membrane protein degradation
- 7 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26218-26233
Degrader-Drug Conjugate (DDC) Mediated Immunochemotherapy for Tumor Treatment
Due to the heterogeneity of tumors and the complex regulatory mechanisms governing PD-L1 expression, immunotherapy that employs PD-1/PD-L1 inhibitors has shown limited efficacy and relatively low response rates. In this work, we propose that a Degrader-Drug Conjugate (DDC), comprising a PD-L1 degrader linked to a cytotoxic agent, may enhance antitumor efficacy by synergizing immune activation with direct cell killing. Mechanistically, the DDC promotes PD-L1 degradation via the endosomal-lysosomal pathway to alleviate immunosuppression, while simultaneously releasing a cytotoxic agent inside tumor cells to induce apoptosis. Among the two DDCs developed in this study, BMS-RGD-MMAE exhibits superior toxin release efficacy, enhanced plasma stability, and increased cytotoxicity compared to BMS-RGD-DXd. Moreover, BMS-RGD-MMAE significantly inhibits tumor growth in vivo through synergistic PD-L1 degradation and toxin-mediated cell death, underscoring its substantial potential for application in tumor immunochemotherapy. Overall, this DDC platform provides new opportunities for the advancement of antitumor therapeutics.
- 7 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (24) , 26218-26233
Degrader-Drug Conjugate (DDC) Mediated Immunochemotherapy for Tumor Treatment
Due to the heterogeneity of tumors and the complex regulatory mechanisms governing PD-L1 expression, immunotherapy that employs PD-1/PD-L1 inhibitors has shown limited efficacy and relatively low response rates. In this work, we propose that a Degrader-Drug Conjugate (DDC), comprising a PD-L1 degrader linked to a cytotoxic agent, may enhance antitumor efficacy by synergizing immune activation with direct cell killing. Mechanistically, the DDC promotes PD-L1 degradation via the endosomal-lysosomal pathway to alleviate immunosuppression, while simultaneously releasing a cytotoxic agent inside tumor cells to induce apoptosis. Among the two DDCs developed in this study, BMS-RGD-MMAE exhibits superior toxin release efficacy, enhanced plasma stability, and increased cytotoxicity compared to BMS-RGD-DXd. Moreover, BMS-RGD-MMAE significantly inhibits tumor growth in vivo through synergistic PD-L1 degradation and toxin-mediated cell death, underscoring its substantial potential for application in tumor immunochemotherapy. Overall, this DDC platform provides new opportunities for the advancement of antitumor therapeutics.
- Open Access
- 14 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7575
Targeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates
Targeted degradation of membrane-associated proteins, which constitute a crucial class of drug targets implicated in diverse disease pathologies, has garnered considerable attention in chemical biology and drug discovery recently. Taking advantage of the endosomal entrapment of cell-penetrating peptides (CPPs) in delivering bioactive macromolecules, we successfully construct a CPP-based platform for specific degradation of cell surface proteins by conjugation of target protein-binding small molecules (SMs) with different CPPs, resulting in the formation of CPP-mediated lysosome-targeting chimeras (CPPTACs). Through the endo-lysosomal pathway, CPPTACs exhibit a remarkable ability to degrade clinically significant plasma membrane proteins, including PD-L1, CAIX, and CB2R. In contrast to LYTACs and similar technologies, CPPTACs drive the degradation of targets in a manner independent of specific lysosome-shuttling receptors, thus providing a widely applicable strategy for plasma membrane protein degradation, regardless of the cell types. Additionally, simpler structural design and broader therapeutic window for CPPTACs are expected since CPPs-mediated endocytosis and lysosomal degradation do not necessitate the three-component binding model typically required by other heterobifunctional degraders. Overall, consisting of small molecules and biocompatible cell-penetrating peptides, CPPTACs developed in this study represent a simple, adaptable, and effective approach for selectively degrading cell surface proteins in various cellular contexts with potential for application in both biological research and therapeutic interventions.
- 14 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7575
Open AccessTargeted degradation of cell surface proteins through endocytosis triggered by cell-penetrating peptide-small molecule conjugates
Targeted degradation of membrane-associated proteins, which constitute a crucial class of drug targets implicated in diverse disease pathologies, has garnered considerable attention in chemical biology and drug discovery recently. Taking advantage of the endosomal entrapment of cell-penetrating peptides (CPPs) in delivering bioactive macromolecules, we successfully construct a CPP-based platform for specific degradation of cell surface proteins by conjugation of target protein-binding small molecules (SMs) with different CPPs, resulting in the formation of CPP-mediated lysosome-targeting chimeras (CPPTACs). Through the endo-lysosomal pathway, CPPTACs exhibit a remarkable ability to degrade clinically significant plasma membrane proteins, including PD-L1, CAIX, and CB2R. In contrast to LYTACs and similar technologies, CPPTACs drive the degradation of targets in a manner independent of specific lysosome-shuttling receptors, thus providing a widely applicable strategy for plasma membrane protein degradation, regardless of the cell types. Additionally, simpler structural design and broader therapeutic window for CPPTACs are expected since CPPs-mediated endocytosis and lysosomal degradation do not necessitate the three-component binding model typically required by other heterobifunctional degraders. Overall, consisting of small molecules and biocompatible cell-penetrating peptides, CPPTACs developed in this study represent a simple, adaptable, and effective approach for selectively degrading cell surface proteins in various cellular contexts with potential for application in both biological research and therapeutic interventions.
- Open Access
- 8 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6576
Targeted Degradation Technologies Utilizing Autophagy
Targeted degradation technologies, primarily referring to targeted protein degradation, have emerged as promising drug discovery strategies. In contrast to traditional “occupancy-driven” inhibition approaches, these technologies ingeniously leverage the cell’s endogenous degradation mechanisms to achieve specific elimination of disease-causing targets. Autophagy, a highly conserved cellular clearance pathway, possesses broad substrate recognition capabilities, enabling degradation of not only individual proteins but also protein aggregates, damaged organelles, and invading pathogens. Given these characteristics, researchers are actively exploring the application of autophagy mechanisms in targeted degradation technologies. Herein, we summarize recent advances in autophagy-dependent degradation approaches, including autophagosome tethering compounds (ATTEC), autophagy-targeting chimeras (AUTAC), autophagy-targeting Chimera (AUTOTAC), chaperone-mediated autophagy (CMA)-based methods, nanotechnology-based strategies, and the newly introduced autophagy-induced antibody (AUTAB) technique, highlighting their mechanisms, advantages, and potential applications in treating tumors, neurodegenerative diseases, and other challenging conditions.
- 8 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6576
Open AccessTargeted Degradation Technologies Utilizing Autophagy
Targeted degradation technologies, primarily referring to targeted protein degradation, have emerged as promising drug discovery strategies. In contrast to traditional “occupancy-driven” inhibition approaches, these technologies ingeniously leverage the cell’s endogenous degradation mechanisms to achieve specific elimination of disease-causing targets. Autophagy, a highly conserved cellular clearance pathway, possesses broad substrate recognition capabilities, enabling degradation of not only individual proteins but also protein aggregates, damaged organelles, and invading pathogens. Given these characteristics, researchers are actively exploring the application of autophagy mechanisms in targeted degradation technologies. Herein, we summarize recent advances in autophagy-dependent degradation approaches, including autophagosome tethering compounds (ATTEC), autophagy-targeting chimeras (AUTAC), autophagy-targeting Chimera (AUTOTAC), chaperone-mediated autophagy (CMA)-based methods, nanotechnology-based strategies, and the newly introduced autophagy-induced antibody (AUTAB) technique, highlighting their mechanisms, advantages, and potential applications in treating tumors, neurodegenerative diseases, and other challenging conditions.
- Top Cited PapersOpen Access
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Linker-free PROTACs efficiently induce the degradation of oncoproteins
Proteolysis-targeting chimeras (PROTACs) present a potentially effective strategy against various diseases via selective proteolysis. How to increase the efficacy of PROTACs remains challenging. Here, we explore the necessity of the linker, which has been deemed as an integral part of heterobifunctional PROTACs. Adopting single amino acid-based degradation signals, we find that the linker is not a required feature of the PROTACs. Notably, the linker-free PROTAC, Pro-BA, exhibits superior efficacy over its linker-bearing counterparts in degrading EML4-ALK and inhibiting lung cancer cell growth, as Pro-BA induces a stronger interaction between the target and the E3 ubiquitin ligase. Pro-BA is a water-soluble, orally administered degrader that significantly inhibits the tumor growth in a xenograft mouse model. The broad applicability of this linker-free PROTAC strategy is further validated through the development of BCR-ABL degrader. Our study introduces a design paradigm for PROTACs, potentially facilitating the advancement of more efficient therapeutic degraders.
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Top Cited PapersOpen AccessLinker-free PROTACs efficiently induce the degradation of oncoproteins
Proteolysis-targeting chimeras (PROTACs) present a potentially effective strategy against various diseases via selective proteolysis. How to increase the efficacy of PROTACs remains challenging. Here, we explore the necessity of the linker, which has been deemed as an integral part of heterobifunctional PROTACs. Adopting single amino acid-based degradation signals, we find that the linker is not a required feature of the PROTACs. Notably, the linker-free PROTAC, Pro-BA, exhibits superior efficacy over its linker-bearing counterparts in degrading EML4-ALK and inhibiting lung cancer cell growth, as Pro-BA induces a stronger interaction between the target and the E3 ubiquitin ligase. Pro-BA is a water-soluble, orally administered degrader that significantly inhibits the tumor growth in a xenograft mouse model. The broad applicability of this linker-free PROTAC strategy is further validated through the development of BCR-ABL degrader. Our study introduces a design paradigm for PROTACs, potentially facilitating the advancement of more efficient therapeutic degraders.